Sequencing-Based Tropism Testing for HIV May Be Feasible, if Not Yet Commercially Viable | GenomeWeb

By Monica Heger

Sequencing could be used
to detect whether Pfizer's HIV drug Selzentry will be effective for individual patients, according to researchers from the Institute for Immunology and Genetics in Kaiserslautern, Germany.

Testing the ability of Roche's 454 GS FLX to detect viral tropism in HIV, the team sequenced the viruses of 14 patients, selecting specifically for the V3 loop of the virus, the region that allows it to infect human immune cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.